Free Trial

111 (YI) Competitors

$1.23
0.00 (0.00%)
(As of 05/30/2024 ET)

YI vs. PETS, CJJD, CVS, WBA, ALLO, LXRX, TBPH, OCGN, BTMD, and FBLG

Should you be buying 111 stock or one of its competitors? The main competitors of 111 include PetMed Express (PETS), China Jo-Jo Drugstores (CJJD), CVS Health (CVS), Walgreens Boots Alliance (WBA), Allogene Therapeutics (ALLO), Lexicon Pharmaceuticals (LXRX), Theravance Biopharma (TBPH), Ocugen (OCGN), biote (BTMD), and FibroBiologics (FBLG).

111 vs.

111 (NASDAQ:YI) and PetMed Express (NASDAQ:PETS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings.

PetMed Express has lower revenue, but higher earnings than 111. PetMed Express is trading at a lower price-to-earnings ratio than 111, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
111$2.11B0.05-$43.07M-$0.62-1.98
PetMed Express$256.86M0.33$5.14M-$0.39-10.38

In the previous week, 111 had 8 more articles in the media than PetMed Express. MarketBeat recorded 14 mentions for 111 and 6 mentions for PetMed Express. PetMed Express' average media sentiment score of 0.86 beat 111's score of 0.24 indicating that PetMed Express is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
111
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral
PetMed Express
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

PetMed Express received 23 more outperform votes than 111 when rated by MarketBeat users. However, 61.69% of users gave 111 an outperform vote while only 45.13% of users gave PetMed Express an outperform vote.

CompanyUnderperformOutperform
111Outperform Votes
190
61.69%
Underperform Votes
118
38.31%
PetMed ExpressOutperform Votes
213
45.13%
Underperform Votes
259
54.87%

21.3% of 111 shares are owned by institutional investors. Comparatively, 73.3% of PetMed Express shares are owned by institutional investors. 43.9% of 111 shares are owned by insiders. Comparatively, 3.6% of PetMed Express shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

111 has a net margin of -2.55% compared to PetMed Express' net margin of -2.92%. 111's return on equity of 0.00% beat PetMed Express' return on equity.

Company Net Margins Return on Equity Return on Assets
111-2.55% N/A -12.13%
PetMed Express -2.92%-1.25%-0.75%

PetMed Express has a consensus price target of $6.50, suggesting a potential upside of 60.49%. Given PetMed Express' higher possible upside, analysts clearly believe PetMed Express is more favorable than 111.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
111
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
PetMed Express
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

111 has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, PetMed Express has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Summary

PetMed Express beats 111 on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

YI vs. The Competition

Metric111Drug stores & proprietary stores IndustryMedical SectorNASDAQ Exchange
Market Cap$105.19M$9.32B$5.04B$7.96B
Dividend YieldN/A5.60%2.84%3.99%
P/E Ratio-1.982.46165.9818.23
Price / Sales0.050.232,437.8970.15
Price / CashN/A4.8935.0631.24
Price / Book-1.260.665.584.64
Net Income-$43.07M$647.08M$105.68M$213.60M
7 Day Performance2.50%-0.74%0.89%1.02%
1 Month Performance18.27%0.89%3.03%3.89%
1 Year Performance-50.60%-52.37%6.15%7.72%

111 Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PETS
PetMed Express
1.3044 of 5 stars
$4.05
-0.7%
$6.50
+60.5%
-72.3%$85.66M$256.86M-10.38302Short Interest ↓
CJJD
China Jo-Jo Drugstores
0 of 5 stars
$2.75
-5.2%
N/A-80.9%$3.25M$148.81M0.00885Analyst Forecast
Gap Down
CVS
CVS Health
5 of 5 stars
$56.04
+4.4%
$75.05
+33.9%
-16.5%$70.35B$357.78B9.85300,000Analyst Forecast
Short Interest ↓
WBA
Walgreens Boots Alliance
4.7074 of 5 stars
$15.39
+3.4%
$24.36
+58.3%
-48.6%$13.28B$144.60B-2.20331,000Options Volume
ALLO
Allogene Therapeutics
3.0983 of 5 stars
$2.46
+5.6%
$9.80
+298.4%
-52.6%$420.29M$90,000.00-1.37232Short Interest ↑
LXRX
Lexicon Pharmaceuticals
1.5816 of 5 stars
$1.70
+3.7%
$5.00
+194.1%
-41.4%$418.61M$1.20M-2.05285Positive News
TBPH
Theravance Biopharma
1.5671 of 5 stars
$8.49
+2.4%
$20.50
+141.5%
-23.4%$412.87M$57.42M-9.87359Analyst Downgrade
OCGN
Ocugen
0.7731 of 5 stars
$1.59
-2.5%
$4.67
+193.5%
+246.9%$409.16M$6.04M-6.3665
BTMD
biote
1.2947 of 5 stars
$6.56
-2.4%
$8.11
+23.6%
+18.0%$406.98M$185.36M59.64194Positive News
FBLG
FibroBiologics
0 of 5 stars
$12.32
-4.9%
N/AN/A$403.11MN/A0.0010Positive News

Related Companies and Tools

This page (NASDAQ:YI) was last updated on 5/31/2024 by MarketBeat.com Staff

From Our Partners